Platinum‑sensitive recurrent ovarian cancer and olaparib maintenance treatment – case report
Prof. MUDr. Michal Zikán, Ph.D.
Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha
Poly(ADP-ribose) polymerase inhibitors (PARP) represent the most modern approach to ovarian cancer treatment. This treatment is exclusive for individuals harbouring germline or somatic BRCA1 or BRCA2 gene mutations. This case report presents a patient with recurrent ovarian cancer treated with oral PARP inhibitor olaparib as a part of third line treatment. Well tolerated treatment led to excellent long-term survival and quality of life.
BRCA1, BRCA2, ovarian carcinoma, PARP inhibition, olaparib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...